Freestone Grove Partners LP Takes $9.07 Million Position in Teleflex Incorporated $TFX

Freestone Grove Partners LP purchased a new stake in shares of Teleflex Incorporated (NYSE:TFX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 71,554 shares of the medical technology company’s stock, valued at approximately $9,070,000. Freestone Grove Partners LP owned approximately 0.17% of Teleflex as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Teleflex during the 2nd quarter valued at $688,537,000. Jupiter Topco LLC bought a new position in shares of Teleflex in the 2nd quarter worth about $550,456,000. Janus Henderson Group PLC lifted its position in Teleflex by 1.1% during the 1st quarter. Janus Henderson Group PLC now owns 4,291,311 shares of the medical technology company’s stock valued at $513,281,000 after acquiring an additional 45,199 shares during the period. AQR Capital Management LLC boosted its stake in Teleflex by 478.1% during the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock worth $287,603,000 after acquiring an additional 1,956,811 shares in the last quarter. Finally, State Street Corp boosted its stake in Teleflex by 1.5% during the fourth quarter. State Street Corp now owns 1,478,776 shares of the medical technology company’s stock worth $180,470,000 after acquiring an additional 22,111 shares in the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Get Teleflex alerts:

Teleflex Stock Performance

Shares of TFX stock opened at $139.81 on Friday. The company has a market capitalization of $5.92 billion, a price-to-earnings ratio of -6.00, a price-to-earnings-growth ratio of 0.92 and a beta of 0.81. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.12 and a current ratio of 2.60. Teleflex Incorporated has a one year low of $100.18 and a one year high of $145.00. The company’s 50-day moving average is $133.86 and its 200 day moving average is $125.91.

Teleflex (NYSE:TFX – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.48. The business had revenue of $570.33 million during the quarter, compared to analysts’ expectations of $559.59 million. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The business’s revenue for the quarter was up 28.9% compared to the same quarter last year. During the same period in the previous year, the company earned $3.73 earnings per share. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Sell-side analysts expect that Teleflex Incorporated will post 7.26 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Friday, August 14th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Friday, August 14th. Teleflex’s payout ratio is presently -5.84%.

Analysts Set New Price Targets

A number of brokerages have weighed in on TFX. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a research note on Wednesday, June 24th. Truist Financial lifted their target price on shares of Teleflex from $143.00 to $150.00 and gave the company a “hold” rating in a report on Monday, August 10th. Raymond James Financial reissued an “outperform” rating and issued a $150.00 price target on shares of Teleflex in a research report on Friday, May 8th. UBS Group upped their price target on Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Finally, BMO Capital Markets assumed coverage on Teleflex in a research report on Wednesday, July 8th. They set an “outperform” rating and a $159.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $152.90.

Read Our Latest Stock Report on Teleflex

About Teleflex

(Free Report)

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.

Featured Stories

• Five stocks we like better than Teleflex
• 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
• IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
• Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
• Okta Stock Surges 29%—Is $200 the Next Stop?

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.